A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (clinicaltrials.gov) - Oct 20, 2026 - P2 | N=37 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2026 ➔ Jun 2027
Checkpoint inhibition • IO biomarker • Trial completion date • Trial primary completion date • Tumor mutational burden • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • ATRX • CDKN2A • CDKN2B • EGFR • TERT • TP53
|